ABLYNX PROVIDES AN R&D UPDATE AND ANNOUNCES RECENT TECHNOLOGY
ADVANCES
(Thomson Reuters ONE) - GHENT, Belgium, 19 October, 2009 - Ablynx [Euronext Brussels: ABLX],announces that it will present an update of its therapeutic pipelineand its recent advances with its Nanobody® technology platform atAblynx's R&D Update in Ghent today. The Company will also illustratethe specific advantages of the Nanobody® platform compared with somedirectly competing technologies.Ablynx now has over 20 programmes in its therapeutic pipelineincluding three Nanobodies® in clinical trials. Ablynx initiated itsfirst Phase II study at the beginning of September for its leadprogramme ALX-0081. Also in September, Ablynx's partner WyethPharmaceuticals initiated a Phase II study with an anti-TNF-alphaNanobody® to combat inflammatory diseases such as rheumatoidarthritis. Nanobodies® have been generated against over 150 differenttargets including several complex targets such as chemokines, GPCRsand viruses, which are typically extremely difficult to approach withconventional monoclonal antibodies."In the last 12 months we have made important progress in deliveringNanobodies® through alternative routes of administration. We will nowbe able to apply these delivery routes within our therapeuticprogrammes. We continue to illustrate the differentiating advantagesof our technology over those of our competitors. We are delightedwith the progress of our clinical programme and anticipate there willbe four Nanobodies® in the clinic by the end of this year, two inPhase II and two in Phase I", said Dr Edwin Moses, CEO and Chairmanof Ablynx.The R&D Review Day presentation will be available on the Company'swebsite as of 4:00 pm CET [10:00 am EST] today-http://www.ablynx.com/investorrelations/eventsandpresentations.php. -ends-For more information, please contact:College Hill Life Sciences - for UK/International media enquiries:Sue Charles, Justine Lamond, John McIntyret: +44 (0)20 7866 7857f: +44 (0)20 7866 7900e: ablynx(at)collegehill.comAblynx:Dr Edwin MosesChairman and CEOt: +32 (0)9 262 00 07m: +44 (0)7771 954 193 / +32 (0)473 39 50 68e: edwin.moses(at)ablynx.comEva-Lotta AllanChief Business Officert: +32 (0)9 262 00 75m: +32 (0)475 78 36 21 / +44 (0)7990 570 900e: eva-lotta.allan(at)ablynx.comhttp://hugin.info/137912/R/1348092/324321.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 19.10.2009 - 08:30 Uhr
Sprache: Deutsch
News-ID 7045
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 249 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX PROVIDES AN R&D UPDATE AND ANNOUNCES RECENT TECHNOLOGY
ADVANCES"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
